## **Accelerating Takeda's R&D Success**



MIT Research and Development Conference November 16, 2017

Andy Plump, M.D., Ph.D. Chief Medical & Scientific Officer Takeda Pharmaceutical Co., Ltd.

#### **Our Mission is to Serve Patients**





We do more than develop medicines

We innovate to improve patients' lives

Takeda R&D places the patient at the center of everything we do

#### The Healthcare Industry is Immensely Dynamic, Facing both Opportunities and Headwinds




- Insight into the Mechanisms of Disease
- Emerging Therapeutic Modalities
- Genomics/Big Data
- The Rewards of Innovation
- Patient Advocacy

- Competition for Enrollment in Clinical Trials
- Cost of Trials
- Established Standard of Care
- Comparative Efficacy (HTA)
- Impact of Unethical Behaviors



#### **Takeda's History**





### Period of Poor Productivity Following Approval of Pioglitazone in 1999



Product Launches by Discovery Source (FY2005 – 2015)		
Internal (4)	Acquisition (8)	Licensed (9)
Dexilant	Alogliptin (Nesina)	Adcetris
Edarbi / Azilva <sup>1</sup>	Colcyrs <sup>2</sup>	Amitiza
Rozerem	Daxas	Azilect
Takecab	Entyvio	Brintellix
	Ninlaro	Contrave <sup>4</sup>
	Revestive <sup>3</sup>	Copaxone
	Trelagliptin (Zafatek)	Galantamine
	Vectibix	Mepact
		Xeljanz



1.For purposes of NME counts, Edarbi and Azilva are combined.


2.Colcrys is counted as an NME, although the product was on-market in generic form.

3.Revestive has been returned to partner: no revenues in Takeda LRF.

4.Contrave is counted as an NME, although it is composed of two on-market products.

#### **R&D – Four Priority Areas**





#### 1) Focus: Core Therapeutic Areas






### 2) New Capabilities: What's Driving Innovation Today



Source: Pharmaprojects 2014; McKinsey analysis



1 E.g., nanotechnologies, bioelectronics, virus particles

2 Currently ~ 60% of global clinical pipeline

#### New Capabilities, cont.






#### 3) External Innovation/Partnerships




Our business development team nurtures an ecosystem of academic institutions, nonprofit organizations, venture capital firms and biopharmaceutical peers



#### **External Innovation: 2017 Efforts to Date**





Not all-inclusive. All trademarks and registered trademarks are the property of their respective owners

#### The Biopharma Ecosystem is Exploding Around Us





#### **Drill Down: Mersana Therapeutics**



# Mersana THERAPEUTICS

- Based in Cambridge, Mass., Mersana is a clinical stage antibody drug conjugate (ACD) company developing proprietary technologies to enable improved efficacy, safety and tolerability relative to existing ADC therapies
- Takeda and Mersana entered a strategic partnership granting Takeda rights to Mersana's lead product candidate, XMT-1522.
- The deal also expanded an existing collaboration between the companies to provide Takeda with additional access to Mersana's Fleximer® ACD platform.

# The Boston Globe

Mersana Therapeutics expands partnership with Takeda

### FierceBiotech

#### Partnering

Takeda ups bet on Mersana's armed antibodies to \$1Bplus, snags lead drug rights




Mersana Therapeutics in up to \$300 million deal with Takeda

#### **Scaling our Externalization Efforts**



Shonan Health Innovation Park: Japan's first pharma-led open innovation ecosystem



PHARMACEUTICAL COMPANIES

### 4) Culture



#### TAKEDA RESEARCH & DEVELOPMENT

#### **Dare to Discover**

Patients live in hope of solutions. They inspire us to make daring breakthroughs and deliver the new therapies they seek.

We're building a culture that drives us towards unexpected solutions, allowing our researchers to reach further and **achieve the remarkable.** 

We view every partnership as an opportunity to embolden each other, because innovation comes from surprising places.

